Login / Signup

Targeting p53 in chronic lymphocytic leukemia.

Riccardo MoiaPaola BoggioneAbdurraouf Mokhtar MahmoudAhad Ahmed KodipadRamesh AdhinaveniSruthi SagirajuAndrea PatriarcaGianluca Gaidano
Published in: Expert opinion on therapeutic targets (2020)
The key approach to improve CLL outcome is treatment tailoring in individual patients. BCR and BCL2 inhibitors have significantly improved CLL survival, however TP53 disrupted patients still have a less favorable outcome than wild type cases, possibly because these novel drugs do not directly target p53 and do not restore the function of the disrupted p53 pathway. Emerging innovative molecules in cancer are able to restore the p53 mutant protein and/or potentiate the activity of the p53 wild type protein. If these compounds were confirmed as efficacious also for CLL, they would represent another step forward in the care of high risk CLL patients with TP53 abnormalities.
Keyphrases